EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Risk Factors of Disease Progression in IgA Nephropathy: A Systematic Review and Meta‐Analysis

Dan Xu iD, Minjie Zhang iD, Weiwei Liang iD, Lijiang Fang iD, Feifei Ge iD

Immunity, Inflammation and Disease · 2026-02 · 14 (2)

DOI: 10.1002/iid3.70393 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Immunity, Inflammation and Disease, online erschienen am 27.02.2026. Verfasst von Dan Xu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Laboratory, Xian Yang Central Hospital, Xianyang, China. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA, Kidney Failure, Chronic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

IgA nephropathy (IgAN) is an important cause of chronic renal failure, and nearly all patients with IgAN are at risk of developing to end‐stage renal disease (ESRD) during their lifetime. This meta‐analysis aimed to identify and evaluate risk factors associated with the progression of IgAN patients.

Methods

Primary studies investigating the risk factors for predicting the progression of IgAN were included in this review. A comprehensive literature search was conducted across multiple electronic databases, including the Chinese Biological Medicine Database (CBM), China National Knowledge Infrastructure (CNKI), Cochrane Library, PubMed, Embase, Web of Science, and WANFANG, up to May 30, 2025. Two independent reviewers screened the literature based on the predefined inclusion and exclusion criteria, extracted the relevant data from the original studies, and assessed the quality of the included studies using the Newcastle‐Ottawa Scale (NOS). Meta‐analysis was performed on at least two studies reporting on a specific outcome, with pooled effect sizes expressed as hazard ratios (HRs) and 95% confidence intervals (CIs). Statistical analysis, including meta‐analysis, subgroup analysis and sensitivity analysis, was conducted using the R software. Publication bias was evaluated using Egger's test in Stata12.0.

Results

A total of 53 studies, comprising 25,517 patients with IgAN, were included in the final analysis. This meta‐analysis identified 10 clinical risk factors significantly associated with IgAN progression, including mean arterial pressure (MAP) (HR = 1.02, 95% CI: 1.01–1.03), diastolic blood pressure (DBP) (HR = 1.03, 95% CI: 1.01–1.05), systolic blood pressure (SBP) (HR = 1.03, 95% CI: 1.01–1.05), serum creatinine (SCr) (HR = 1.04, 95% CI: 1.03–1.06), triglyceride (HR = 1.11, 95% CI: 1.02–1.21), 24‐h urinary protein excretion (UPE) (HR = 1.15, 95% CI: 1.12–1.18), low‐density lipoprotein cholesterol (LDL‐C) (HR = 1.37, 95% CI: 1.18–1.59), male sex (vs. female) (HR = 1.73, 95% CI: 1.16–2.59), complement C4 (C4) (HR = 1.81, 95% CI: 1.06–3.09), and hypertension (HR = 2.53, 95% CI: 1.92–3.33). The pathological features significantly predictive of IgAN progression including crescents (C1/C2) (vs. C0) (HR = 1.57, 95% CI: 1.24–1.99), C2 (vs. C0) (HR = 2.87, 95% CI: 1.65–5.01), endocapillary hypercellularity (E1) (vs. E0) (HR = 1.17, 95% CI: 1.02–1.35), segmental glomerulosclerosis (S1) (vs. S0) (HR = 2.23, 95% CI: 1.78–2.79), and tubular atrophy (T1/T2) (vs. T0) (HR = 5.12, 95% CI: 3.56–7.36), when analyzed individually, T1 (vs. T0) showed an HR = 4.59 (95% CI: 3.24–6.51), and T2 (vs. T0) showed an HR = 16.40 (95% CI: 9.65–27.87). In contrast, C1 (vs. C0) (HR = 1.41, 95% CI: 0.81–2.45) was not significantly associated with progression risk. Protective factors against lgAN progression included higher level of albumin (Alb) (HR = 0.95, 95% CI: 0.93–0.98), estimated glomerular filtration rate (eGFR) (HR = 0.96, 95% CI: 0.95–0.97), hemoglobin (Hb) (HR = 0.98, 95% CI: 0.97–0.99), complement C3 (C3) (HR = 0.97, 95% CI: 0.95–0.99). Additionally, female sex was associated with a lower risk of disease progression, with HR = 0.69 (95% CI: 0.57–0.84) and when compared directly with male HR = 0.55 (95% CI: 0.45–0.67).

Conclusion

This meta‐analysis indicates that MAP, DBP, SBP, SCr, triglyceride, 24‐h UPE, LDL‐C, male sex (vs. female), C4, hypertension, C‐lesions, M‐lesions, S‐lesions, and T‐lesions in Oxford classification are significantly associated with an increased risk of IgAN progression. In contrast, higher levels of Alb, eGFR, Hb, C3, as well as female sex (both as an independent variable and compared with males), are identified as protective factors in patients with IgAN.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerulonephritis, IGAKidney Failure, ChronicHumansDisease ProgressionRisk FactorsFemale

Stichwörter der Autor:innen

IgA nephropathyend‐stage renal diseasekidney disease progressionmeta‐analysisrisk factorsthe Oxford classification

Autor:innen und Institutionen

  • Department of Medical Laboratory, Xian Yang Central Hospital, Xianyang, China.
  • Department of Medical Laboratory, The Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, China.
  • Department of Medical Laboratory, The Second Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, China.
  • Department of Hemodialysis, Xian Yang Central Hospital, Xianyang, China.

ORCID-Profile: Dan Xu, Minjie Zhang, Weiwei Liang, Lijiang Fang, Feifei Ge

Zitieren

APA

Xu, D., Zhang, M., Liang, W., Fang, L., & Ge, F. (2026). Risk Factors of Disease Progression in IgA Nephropathy: A Systematic Review and Meta‐Analysis. Immunity, Inflammation and Disease, 14(2). https://doi.org/10.1002/iid3.70393

Vancouver

Xu D, Zhang M, Liang W, Fang L, Ge F. Risk Factors of Disease Progression in IgA Nephropathy: A Systematic Review and Meta‐Analysis. Immunity, Inflammation and Disease. 2026;14(2). doi:10.1002/iid3.70393

BibTeX
@article{Xu2026,
  author = {Xu, Dan and Zhang, Minjie and Liang, Weiwei and Fang, Lijiang and Ge, Feifei},
  title = {Risk Factors of Disease Progression in IgA Nephropathy: A Systematic Review and Meta‐Analysis},
  journal = {Immunity, Inflammation and Disease},
  year = {2026},
  volume = {14},
  number = {2},
  doi = {10.1002/iid3.70393}
}
Kostenlos starten →